Michael C. Heinrich, M.D.

Academic and Clinical Position

Professor

Biography

Dr. Heinrich provides expert care for patients with gastrointestinal stromal tumors (GIST). He is one of a handful of GIST experts on the West Coast. As part of his research program, Dr. Heinrich has authored more than 30 papers on clinical and molecular aspects of GIST and helped design and conduct the Phase II and III studies that led to FDA approval of imatinib (Gleevec) and sunitinib (Sutent) for GIST. In addition, Dr. Heinrich's GIST clinic offers clinical studies of investigational agents for patients with advanced disease and expert molecular diagnostic consultation.

Dr. Heinrich also specializes in head and neck cancer and participates in the multidisciplinary care of these patients with members of the OHSU ENT and radiation oncology departments.

Professional Education

• Degree:
  M.D., Johns Hopkins University School of Medicine, 1984
  
• Residency:
  Oregon Health & Science University, 1988
• Fellowship:
  Hematology/Medical Oncology, Oregon Health & Science University, 1991

Certifications

• Certifications:
  American Board of Internal Medicine, (Internal Medicine), 1987
  American Board of Internal Medicine (Hematology), 1990 (Recertified 2000)
  American Board of Internal Medicine, (Medical Oncology), 1991 (Recertified 2001)

Memberships and Associations

American Society of Clinical Oncology
American Society of Hematology
Fellow, American College of Physicians
American Association of Cancer Research
Alpha Omega Alpha

Additional Information

Additional special interests

Development of novel tyrosine kinase inhibitors for treatment of human cancers